Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

SHC - Sotera Health Company Latest News | Finranks

Home

/

SHC

S

Sotera Health Company (SHC)

NMS – Real Time Price. Currency in USD

18.85

-0.26 (-1.36%)

Market open: Aug 12, 2026, 10:13 AM EDT

19.11

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Sotera Health Q2 Earnings Call Highlights

Sotera Health Q2 Earnings Call Highlights

Sotera Health NASDAQ: SHC reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook.

Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript

Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript

Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript

Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates

Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates

Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.2 per share a year ago.

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025 Q2 2026 Adjusted EBITDA ( 1 ) increased 10.0%, or 8.7% on a constant currency basis Q2 2026 Adjusted EPS (1) of $0.26, an increase of 30% per diluted share Company raises both full-year 2026 net revenues growth out look to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5.75% - 7.25%, on a constant currency basis CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026. “We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units,” said Chief Executive Officer Alton Shader.

Videos

No Data

There is no data to display

Press releases

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025 Q2 2026 Adjusted EBITDA ( 1 ) increased 10.0%, or 8.7% on a constant currency basis Q2 2026 Adjusted EPS (1) of $0.26, an increase of 30% per diluted share Company raises both full-year 2026 net revenues growth out look to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5.75% - 7.25%, on a constant currency basis CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026. “We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units,” said Chief Executive Officer Alton Shader.